A pilot trial of combination therapy with interferon alfacon-1, ribavirin, and rosiglitazone in a group of insulin resistant, chronic hepatitis C, genotype 1 patients who are previous relapsers or nonresponders to pegylated interferon [peginterferon-alpha] and ribavirin.

Trial Profile

A pilot trial of combination therapy with interferon alfacon-1, ribavirin, and rosiglitazone in a group of insulin resistant, chronic hepatitis C, genotype 1 patients who are previous relapsers or nonresponders to pegylated interferon [peginterferon-alpha] and ribavirin.

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Feb 2012

At a glance

  • Drugs Rosiglitazone (Primary) ; Interferon alfacon-1; Ribavirin
  • Indications Hepatitis C; Insulin resistance
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Feb 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 13 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 30 Jun 2009 Planned number of patients changed from 40 to 34, additional lead trial centres and lead trial investigators as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top